drugset / Trial / NCT00040157

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.

NCT00040157

Phase 2 Terminated 60 enrolled Alexion Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine safety and efficacy of ACH-126,443 on the treatment of adults with HIV infection who have modestly detectable viral load while on stable triple combination antiretroviral therapy including 3TC.

Timeline

Start
Primary completion
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Elvucitabine Small molecule